Cancer Clinical Trial
— SEAMLESSOfficial title:
The SEAMLESS Study: A Pragmatic Multi-Site Randomized Waitlist-Controlled Trial of a Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors
NCT number | NCT05470010 |
Other study ID # | SC28 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 30, 2024 |
Est. completion date | December 31, 2026 |
There is a need to develop, evaluate, and disseminate self-directed, easily accessible, safe, affordable, and effective psychosocial interventions to people living with cancer (PLWC) post-treatment. Smartphone app-based health interventions are an innovative way to deliver psychosocial cancer-care. The Mindfulness-Based Cancer Survivorship (MBCS) Journey app is a mobile app format of the Mindfulness-based Cancer Recovery program. In the SEAMLESS Study, the investigators aim to evaluate the MBCS Journey app (a 4 week mind-body intervention) in cancer survivors post-treatment. This is a randomized wait-list controlled trial. Participants will either be assigned into the immediate group (will receive intervention immediately after enrollment) or the waitlist group (wait for 3 months before receiving the intervention).
Status | Recruiting |
Enrollment | 345 |
Est. completion date | December 31, 2026 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult = 18 years - Diagnosed with any type of cancer (stages I-IV) - Completed primary treatment (i.e. surgery, chemotherapy, radiation therapy) at least 2 weeks (14days) prior. Note: ongoing maintenance therapy, hormone-blocking therapies, intermittent bone-modifying agents, herceptin and targeted therapy with trastuzumab are not exclusionary. - Have access to a smartphone with data or wifi connection. - Willing to devote 20-30 mins of time to mindfulness practices daily during the 4-week intervention period. - Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form (e-consent) prior to enrollment in the study to document their willingness to participate. - Participant is able (i.e. sufficiently fluent) and willing to complete the MBCS Journey and outcome measures in either English or French. The baseline assessment must be completed within required timelines, prior to randomization. - In accordance with CCTG policy, protocol intervention is intended to begin within 7 calendar days of patient randomization. - Participants must be willing to complete the MBCS Journey and complete the follow-up questionnaires Exclusion Criteria: - Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or cognitive impairment (score of = 6;assessed using three questions from the Brief Screen for Cognitive Impairment (BSCI)), which could interfere with completing the intervention and/or the questionnaires (i.e. inability to read or write) - Suffering from untreated Major Depressive Disorder or other psychiatric disorders that would interfere with participation. (Note: Participants will be referred for treatment and invited to call back once in remission). - Previous experience practicing in-person or app-based mindfulness once a week or more within the last year. |
Country | Name | City | State |
---|---|---|---|
Canada | Tina Nguyen | Calgary |
Lead Sponsor | Collaborator |
---|---|
Canadian Cancer Trials Group | Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Calgary Symptoms of Stress Inventory (C-SOSI) | This is a 56 item scale. Each item is rated on a 5-point Likert scale (1-5). A higher score indicates higher levels of stress. | 3 months | |
Secondary | Patient Reported Outcome Measurement Information System (PROMIS) - Anxiety | PROMIS - Cancer Bank v1.0 - Anxiety. This questionnaire has 22 items, each rated on a 5-point Likert scale. A higher score indicates higher levels of anxiety. | 3 months | |
Secondary | Patient Reported Outcome Measurement Information System (PROMIS) - Depression | PROMIS - Cancer Bank v1.0 - Depression. This questionnaire has 30 items, each rated on a 5-point Likert scale. A higher score indicates higher levels of depression. | 3 months | |
Secondary | Patient Reported Outcome Measurement Information System (PROMIS) - Fatigue | PROMIS - Cancer Bank v1.0 - Fatigue. This questionnaire has 54 items, each rated on a 5-point Likert scale. A higher score indicates higher levels of fatigue. | 3 months | |
Secondary | Patient Reported Outcome Measurement Information System (PROMIS) - Physical Function | PROMIS - Cancer Bank v1.1 - Physical Function. This questionnaire has 45 items, each rated on a 5-point Likert scale. A higher score indicates better physical functioning. | 3 months | |
Secondary | Quality of Life - European Organization for Research and Treatment of Cancer quality of life | European Organization for Research and Treatment of Cancer quality of life - EORTC QLQ C-30. The two items measuring quality of life were used. Each item is rated on a 7-point Likert scale (1-7). | 3 months | |
Secondary | App-based User Data - Perceived Stress | Perceived stress will be measured using a stress slider within the app. | 3 months | |
Secondary | App-based User Data - Mood | Mood will be measured using a mood board. | 3 months | |
Secondary | App-based User Data - Objective Stress | Biometric imaging will be used to measure heart rate and blood flow which combined will predict the participant's "objective stress". | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|